Loss of antiphospholipid antibody positivity post-thrombosis in SLE

被引:18
作者
Khawaja, Muznay [1 ]
Magder, Laurence [2 ]
Goldman, Daniel [3 ]
Petri, Michelle A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21205 USA
[2] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
[3] Johns Hopkins Univ, Rheumatol, Baltimore, MD USA
关键词
antibodies; antiphospholipid; anticardiolipin; lupus erythematosus; systemic; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTERNATIONAL CONSENSUS STATEMENT; US COHORT LUMINA; VIPER VENOM TIME; RISK-FACTORS; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; RECURRENT THROMBOSIS; ARTERIAL THROMBOSIS; CLINICAL-COURSE;
D O I
10.1136/lupus-2020-000423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose Loss of positivity of antiphospholipid antibodies has been observed in clinical practice post-thrombosis in patients with SLE with secondary antiphospholipid syndrome (APS). Our study defined the frequency of this loss and the duration before positivity recurred. Methods In this prospective study, patients with SLE having at least two positive antiphospholipid markers prior to thrombosis and at least 1 year of follow-up after thrombosis were included. Antiphospholipid markers included lupus anticoagulant (dilute Russell viper venom test >45 s followed by mixing and confirmatory tests) and/or anticardiolipin titre (aCL IgG >= 20, aCL IgM >= 20 and/or aCL IgA >= 20). The percentage of visits with positive antiphospholipid markers after thrombosis was calculated. For patients with a negative antiphospholipid marker any time after thrombosis, survival estimates were performed to calculate the time to return of antiphospholipid positivity. Results In APS due to SLE, complete loss of antiphospholipid positivity post-thrombosis was up to 41% for aCL IgG, 51% for IgM and 50% for IgA, but only 20% for those with lupus anticoagulant. Of those who at some point lost aCL IgG or became negative for lupus anticoagulant, the majority (60% and 76%, respectively) reacquired the antibody within 5 years. In contrast, of those who lost aCL IgM or IgA, fewer reacquired it within 5 years (37% and 17%, respectively). Conclusion Intermittent positivity of antiphospholipid antibodies is present in APS due to SLE. These fluctuations make it difficult to decide on length of anticoagulation. Lupus anticoagulant is more likely to persist post-thrombosis.
引用
收藏
页数:7
相关论文
共 60 条
[31]   Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus [J].
Martincz-Berriotxoa, Agustin ;
Ruiz-Rastorza, Guillermo ;
Egurbide, Maria-Victoria ;
Garmendia, Maider ;
Erdozain, Jose Gabriel ;
Villar, Irama ;
Aguirre, Ciriaco .
LUPUS, 2007, 16 (10) :810-816
[32]   International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J].
Miyakis, S ;
Lockshin, MD ;
Atsumi, T ;
Branch, DW ;
Brey, RL ;
Cervera, R ;
Derksen, RHWM ;
De Groot, PG ;
Koike, T ;
Meroni, PL ;
Reber, G ;
Shoenfeld, Y ;
Tincani, A ;
Vlachoyiannopoulos, PG ;
Krilis, SA .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :295-306
[33]   Incidence and risk factors of thromboembolism in systemic lupus erythematosus - A comparison of three ethnic groups [J].
Mok, CC ;
Tang, SSK ;
To, CH ;
Petri, M .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2774-2782
[34]   Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study [J].
Mustonen, P. ;
Lehtonen, K. V. ;
Javela, K. ;
Puurunen, M. .
LUPUS, 2014, 23 (14) :1468-1476
[35]   Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events [J].
Otomo, Kotaro ;
Atsumi, Tatsuya ;
Amengual, Olga ;
Fujieda, Yuichiro ;
Kato, Masaru ;
Oku, Kenji ;
Horita, Tetsuya ;
Yasuda, Shinsuke ;
Koike, Takao .
ARTHRITIS AND RHEUMATISM, 2012, 64 (02) :504-512
[36]   Clinical Application of Revised Laboratory Classification Criteria for Antiphospholipid Antibody Syndrome: Is the Follow-Up Interval of 12 Weeks Instead of 6 Weeks Significantly Useful? [J].
Park, Sang Hyuk ;
Jang, Seongsoo ;
Park, Chan-Jeoung ;
Chi, Hyun-Sook .
BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[37]   ISTH guidelines on Lupus Anticoagulant testing [J].
Pengo, V. .
THROMBOSIS RESEARCH, 2012, 130 :S76-S77
[38]   Clinical course of high-risk patients diagnosed with antiphospholipid syndrome [J].
Pengo, V. ;
Ruffatti, A. ;
Legnani, C. ;
Gresele, P. ;
Barcellona, D. ;
Erba, N. ;
Testa, S. ;
Marongiu, F. ;
Bison, E. ;
Denas, G. ;
Banzato, A. ;
Jose, S. Padayattil ;
Iliceto, S. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) :237-242
[39]   THE FREQUENCY OF LUPUS ANTICOAGULANT IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A STUDY OF 60 CONSECUTIVE PATIENTS BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, RUSSELL VIPER VENOM TIME, AND ANTICARDIOLIPIN ANTIBODY LEVEL [J].
PETRI, M ;
RHEINSCHMIDT, M ;
WHITINGOKEEFE, Q ;
HELLMANN, D ;
CORASH, L .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (04) :524-531